Effect of the miR-886-5p on the cervical squamous epithelial cell clone formation and cervical cancer chemotherapy

doi:10.3969/j.issn.1006-7795.2015.06.017

Abstract

Abstract: Objective To explore the effect of the miR-886-5p on the cervical squamous epithelial cell clone formation and cervical cancer chemotherapy. Methods Microassay was carried out for cervical squamous cell carcinoma tissues(CSCCs) and adjacent non-tumor tissues. One of them is miR-886-5p that overexpression in CSCCs. Bioinformatics analysis suggests that P53 pathway genes(Bax, P14, GADD45B and 14-3-3δ) are miR-886-5p target genes. With a GFP tag overexpression of miR-886-5p plasmid we evaluated the formation of cervical epithelial cell clone. Downstream target validation was performed for miR-886-5p. MiR-886-5p was validated by RT-PCR after chemotherapy in SiHa cell. Results Forced expression of one miRNA, miR-886-5p, overexpressed in CSCC tissues lowered expression of the protein P14 and P53, promoted cell clone formation in H8, an HPV16-immortalized human cervical squamous epithelial cell line. After the cervical squamous carcinoma cell line was cultured with different amounts of paclitaxel and VP16, the expression of miR-886-5p was significantly upregulated with the increasing concentration of paclitaxel and VP16. Conclusion MiR-886-5p promotes proliferation of cervical cancer cells and contributes to cervical cancer chemotherapy resistance.

Key words: cervical squamous epithelial cell, cervical cancer cell, MiR-886-5p, clone formation, chemotherapy

CLC Number:

R711.74

Li Jinghua, Wang Ming, Zhang Rui, Feng Limin. Effect of the miR-886-5p on the cervical squamous epithelial cell clone formation and cervical cancer chemotherapy[J]. Journal of Capital Medical University, 2015, 36(6): 929-935.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2015.06.017

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2015/V36/I6/929

References

[1] Bray F, Ren J, Masuyer E, et al. Estimates of global cancer prevalence in 2008 for 27 sites in the adult population[J]. Int J Cancer, 2012,132(5):1133-1145.
[2] Formana D, de Martelb C, Laceyc C J, et al.Global burden of human papillomavirus and related diseases[J]. Vauine, 2013,30(Suppl 5):12-23.
[3] Martin C M, Astbury K, O'Leary J J. Molecular profiling of cervical neoplasia[J]. Expert Rev Mol Diagn, 2006,6(2):217-229.
[4] Li J H, Xiao X, Zhang Y N, et al. MicroRNA MiR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells[J]. Gynecol Oncol, 2011,120(1):145-151.
[5] Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials[J]. Eur J Cancer, 2003,39(17):2470-2486.
[6] Wang X, Wang H K, Philip McCoy J, et al. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6[J]. RNA, 2009,15(4):637-647.
[7] Lee J W, Choi C H, Choi J J, et al. Altered microRNA expression in cervical carcinomas[J]. Clin Cancer Res, 2008,14 (9):2535-2542.
[8] Yao Q, Xu H, Zhang Q Q, et al. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4(PDCD4) in HeLa cervical carcinoma cells[J]. Bioche Biophys Res Commun, 2009,388(3):539-542.
[9] Aylon Y, Oren M. New plays in the p53 theater[J]. Curr Opin Genet Dev, 2011,21(1):86-92.
[10] Vousden K H, Prives C. Blinded by the light: the growing compleity of p53[J]. Cell, 2009,137(3):413-431.
[11] Sardi J E, Sananes C E, Giaroli A A, et al. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial[J]. Int J Gyneeol Cancer, 1998,8(6):441-450.
[12] Hwang Y Y, Moon H, Cho S H, et al. Ten-year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy[J]. Gynecol Oncol, 2001,82(1):88-93.
[13] Dong J, Zhao Y P, Zhou L, et al. Bcl-2 upregulation induced by miR-2l Via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells[J]. Arch Med Res, 2011,42(1):8-14.
[14] 刘巧丹,石少权,刘长青,等.宫颈癌术前同期放化疗和新辅助化疗的疗效比较[J].中华肿瘤防治杂志,2012,19(11):860-862,866.
[15] 张荣繁,斯琴高娃,杨昊.中晚期宫颈癌多西他赛联合顺铂化疗同步放疗临床观察[J].中华肿瘤防治杂志,2014,21(20):1641-1644.
[16] Yang H, Kong W, He L, et al. MicroRNA expression profiliIlg in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN[J]. Cancer Res, 2008,68(2):425-433.
[17] Mishm P J, Humeniuk P, Mishra P J, et al. A miR-24 microRNA binding site polymorphism in dihydrofolate reductaSe gene leads to methotrexate resistance[J]. Proc Natl Acad Sci U S A, 2007,104(33):13513-13518.
[18] 巫剑红,代荫梅.肿瘤与microRNA的DNA甲基化相关性研究进展[J].中华肿瘤防治杂志,2012,19(24):1919-1922.
[19] 叶郁红,张声,王行富,等.宫颈癌相关危险因素分析[J].中国医科大学学报,2014,43(7):659-660.